Head to head
KLOW blend against GLOW blend
Two GHK-Cu dominated vendor blends with overlapping ingredient lists, sold for repair and for skin respectively. Neither combination has been tested in any species, and in both the copper peptide is the majority of the mass.
Column A
KLOW blendKLOW (GHK-Cu + KPV + BPC-157 + TB-500)
A four-peptide vendor blend, typically 50 mg GHK-Cu with 10 mg each of KPV, BPC-157 and TB-500, sold for repair and inflammation. No study has tested the combination in any species. GHK-Cu is 62.5% of the powder, so the vial carries roughly 7.9 mg of elemental copper and anyone dosing KLOW by units is mostly dosing a copper peptide.
Column B
GLOW blendGLOW (GHK-Cu + BPC-157 + TB-500)
A three-peptide vendor blend, typically 50 mg GHK-Cu with 10 mg each of BPC-157 and TB-500, marketed for skin and recovery. No study has tested the combination. GHK-Cu is 71.4% of the powder, so the vial carries roughly 7.9 mg of elemental copper and this is closer to a copper peptide vial with two additives than to an equal three-way stack.
Side by side, on the facts we can check
| Attribute | KLOW blend | GLOW blend |
|---|---|---|
| Category | Healing & Recovery | Cosmetic |
| FDA status | Not approved, and the combination has never been evaluated by any regulator. FDA staff evaluated BPC-157 for the July 2026 Pharmacy Compounding Advisory Committee and found no adequate human data along with mislabelled products in the market. | Not approved; the combination has never been evaluated. FDA staff evaluated BPC-157 and TB-500 separately for the July 2026 Pharmacy Compounding Advisory Committee and found no adequate human data for either. |
| Half-life | Not defined for the blend, and the components differ. No pharmacokinetic study of the mixture exists. | Not defined for the blend. No pharmacokinetic study of the mixture exists. |
| Molecular weight | A mixture. GHK-Cu is about 403 Da as the copper complex, KPV 342.4 Da, BPC-157 1,419.5 Da, and the Ac-LKKTETQ fragment sold as TB-500 about 889 Da. | A mixture. GHK-Cu is about 403 Da as the copper complex, BPC-157 1,419.5 Da, and the Ac-LKKTETQ fragment sold as TB-500 about 889 Da. |
| Mechanism | Assumed to be the sum of the parts, and assumed is the operative word. GHK-Cu carries copper into tissue and has been shown in culture and in rat wound chambers to drive collagen and glycosaminoglycan production. KPV is the C-terminal tripeptide of alpha-MSH and blocks NF-kB and MAP kinase signalling in intestinal epithelial and immune cells. BPC-157 and TB-500 act through the tissue-repair pathways described on their own pages. No paper describes what these four do in the same syringe, whether the effects add, overlap or interfere, or whether an acidic copper complex is compatible in solution with three other peptides over the weeks a vial stays in a fridge. | Assumed additive, on no evidence that it is. GHK-Cu delivers copper and drove collagen and glycosaminoglycan production in fibroblast culture and in rat wound chambers. BPC-157 and TB-500 act through the repair pathways set out on their own pages, with the standing caveat that TB-500 is a seven amino acid fragment rather than the thymosin beta 4 protein whose literature is usually quoted for it. No study describes the three together, their compatibility in one acidic copper-containing solution, or a combined dose. |
| Human studies cited | 2 | 3 |
| Legal status, US | Not approved; sold 'for research use only' | Not approved; sold 'for research use only' |
Frequently asked questions
What is the difference between KLOW blend and GLOW blend?
KLOW blend: A four-peptide vendor blend, typically 50 mg GHK-Cu with 10 mg each of KPV, BPC-157 and TB-500, sold for repair and inflammation. No study has tested the combination in any species. GHK-Cu is 62.5% of the powder, so the vial carries roughly 7.9 mg of elemental copper and anyone dosing KLOW by units is mostly dosing a copper peptide. GLOW blend: A three-peptide vendor blend, typically 50 mg GHK-Cu with 10 mg each of BPC-157 and TB-500, marketed for skin and recovery. No study has tested the combination. GHK-Cu is 71.4% of the powder, so the vial carries roughly 7.9 mg of elemental copper and this is closer to a copper peptide vial with two additives than to an equal three-way stack.
Which has stronger research evidence, KLOW blend or GLOW blend?
This database does not grade compounds. It counts what was run in people: 2 of the 10 studies cited on the KLOW blend profile were human work, against 3 of 10 for GLOW blend. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are KLOW blend and GLOW blend FDA-approved?
KLOW blend: Not approved, and the combination has never been evaluated by any regulator. FDA staff evaluated BPC-157 for the July 2026 Pharmacy Compounding Advisory Committee and found no adequate human data along with mislabelled products in the market.. GLOW blend: Not approved; the combination has never been evaluated. FDA staff evaluated BPC-157 and TB-500 separately for the July 2026 Pharmacy Compounding Advisory Committee and found no adequate human data for either..
Related posts
Blog articles that cover KLOW blend or GLOW blend, newest first.
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.